Loading...
Market
What will be the market penetration of HYMPAVZI™ in the EU by 2025?
2
Resolution / Starting Odds
Low (<10%) • 25%
Moderate (10-30%) • 25%
High (30-50%) • 25%
Very High (>50%) • 25%
Market analysis reports from industry analysts
Story
European Commission Approves Pfizer’s HYMPAVZI™ for Severe Hemophilia A or B
Nov 20, 2024, 09:04 AM
The European Commission has approved Pfizer’s HYMPAVZI™ (marstacimab) for the treatment of adults and adolescents with severe hemophilia A or B without inhibitors. This approval marks a significant advancement in the treatment options available for hemophilia patients, providing a new once-weekly therapy. Pfizer announced that the approval will benefit eligible patients in the European Union, offering a new solution for managing this chronic condition.
View original story
Similar markets
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
